• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » HμREL, Sanofi collaborate

HμREL, Sanofi collaborate

October 2, 2013
CenterWatch Staff

HμREL, a provider of advanced tissue constructs and microfluidic cell-based assay platforms for preclinical drug development, has entered into a multi-phase R&D collaboration with Sanofi U.S.

Sanofi will fund a range of studies designed to evaluate the utility of HμREL's cell-based products and technologies for preclinical drug development. Different aspects of the collaboration will be carried out in HμREL's laboratories in North Brunswick, N.J., and  in various Sanofi R&D locations in both the U.S. and Europe. The companies intend to share the results of their collaboration through one or more co-authored, peer-reviewed scientific publications.

The initial phase of the collaboration will aim to validate HμREL's HμRELhumanTM 3D liver tissue co-culture for use across an array of experimental requirements typically addressed during the preclinical phase.

Subsequent phases of the collaboration are planned to broaden the range of validated applications, as well as to cover HμREL's HμRELflow microfluidic assay platform, in which the liquid culture medium containing the molecular entity under study is recirculated in a microfluidic pathway, analogously to how the bloodstream recirculates through the various organs of the body.

HμREL’s patent-pending HμRELhuman in vitro liver tissue construct utilizes a proprietary co-culture of primary cryopreserved human hepatocytes (i.e., actual human liver cells) to deliver highly sensitive and accurate predictions of the liver-mediated effects of drugs on humans.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing